Hepatitis B Boosters Using a Different Product vs. the Same Product for Kidney Transplant Recipients: A Retrospective Study With Bayesian Inference
The crossover strategy hepatitis B vaccines did not appear to lead to seroconversion of much significance among KTR. Other options to augment the protection should be investigated to protect these populations against the infection.
Authors
- Shunkichi Ikegaki (ORCID: https://orcid.org/0000-0002-0411-1061)
- Yoji Hyodo (ORCID: https://orcid.org/0000-0002-9553-0981)
- Kentaro Iwata (ORCID: https://orcid.org/0000-0003-2148-3016)
- Hideaki Miyake
Institutions
- Kobe University Hospital (JP)
- Kobe University (JP)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1111/ctr.70307
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00